PTRA enables clinicians to confidently personalize immunosuppression, reducing adverse events in low-risk patients while strengthening protection against rejection in high-risk patients
Health economic analysis shows potential to save more than $191 million across U.S. for patients preparing for kidney transplant
FRANKLIN, Tenn., July 27, 2026 — Verici Dx, a developer of advanced clinical diagnostics for organ transplant, today announced the publication of a health economic cost impact analysis demonstrating the significant potential cost benefit of the Pre-Transplant Risk Assessment (PTRA™) test for predicting early acute rejection (EAR) in kidney transplant. The study, entitled “Cost Impact of a Novel Pre-transplant Risk Assessment Tool for Early Acute Rejection in Kidney Transplant Patients” and published in the Journal of Health Economics and Outcomes Research, shows that integrating PTRA into standard clinical practice could generate substantial healthcare savings while supporting more personalized immunosuppression strategies.
Key findings of the study, conducted by Avalon Health Economics, included the potential for more than $191 million in healthcare savings across the U.S. standard-risk kidney transplant population over two years
“Kidney transplant recipients require carefully managed immunosuppressive therapy to prevent rejection while minimizing complications due to immunosuppression associated infections, adverse drug events, or malignancies,” said Sara Barrington, Chief Executive Officer of Verici Dx. “However, clinicians currently lack robust tools to accurately stratify patient risk prior to transplantation. This publication highlights the substantial value that a precision diagnostic like PTRA can bring to transplant medicine, supporting more informed clinical decisions, improving patient management, and potentially saving the healthcare system millions of dollars.”
The PTRA test consists of an RNA signature comprised of 29 genes involved in oxidative stress, endothelial injury, metabolic regulation, and immune pathways associated with both T cell– and antibody-mediated mechanisms of rejection. By identifying patients at higher or lower risk, clinicians can tailor immunosuppressive regimens to better match individual immune risk profiles. The PTRA test is commercially marketed by Thermo Fisher Scientific.
The authors note that more intense immunosuppression is often used in patients without clear high-risk characteristics. Based on their study, the authors conclude that incorporating the PTRA test in standard-of-care protocols may allow clinicians to more confidently tailor immunosuppression at a reduced level, reducing medication-related adverse events and unfavorable clinical outcomes. The approach may also allow for more intense immunosuppression for some patients with a high-risk PTRA result, reducing acute rejection and its downstream effects.
“Early acute rejection remains one of the most significant drivers of post-transplant complications, graft injury, and healthcare costs,” said Beatrice Concepcion, MD, Medical Director, Kidney and Pancreas Transplant, University of Chicago Medicine. “Having the ability to stratify rejection risk before transplantation could meaningfully change how we approach immunosuppression. The PTRA test has the potential to help clinicians personalize therapy, escalating treatment for patients who truly need it while avoiding unnecessary exposure in lower-risk patients.”
About Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analyses with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. Operating at the intersection of laboratory and data science, Verici Dx develops complex models to answer the clinical questions that matter most with clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection. The company is headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.
The Pre-Transplant Risk Assessment (PTRA) test is a laboratory developed test, and its performance characteristics determined by the CLIA laboratory performing the test. It has not been cleared or approved by the U.S. Food and Drug Administration or CE marked in the EU.
